Follistatin is a single-chain glycosylated protein whose primary function consists in binding and neutralizing some members of the transforming growth factor-β superfamily such as activin and bone morphogenic proteins. Emerging evidence indicates that this molecule may also play a role in the malignant progression of several human tumors including prostate cancer. In particular, recent findings suggest that, in this tumor, follistatin may also contribute to the formation of bone metastasis through multiple mechanisms, some of which are not related to its specific activin or bone morphogenic proteins’ inhibitory activity. This review provides insight into the most recent advances in understanding the role of follistatin in the prostate cancer progression and discusses the clinical and therapeutic implications related to these findings.

Sepporta, M.V., Tumminello, F.M., Flandina, C., Crescimanno, M., Giammanco, M., La Guardia, M., et al. (2013). Follistatin as potential therapeutic target in prostate cancer. TARGETED ONCOLOGY, 8(00) [DOI 10.1007/s11523-013-0268-7].

Follistatin as potential therapeutic target in prostate cancer

TUMMINELLO, Francesca Maria;FLANDINA, Carla;CRESCIMANNO, Marilena;GIAMMANCO, Marco;LA GUARDIA, Maurizio;DI MAJO, Danila;LETO, Gaetano
2013-01-01

Abstract

Follistatin is a single-chain glycosylated protein whose primary function consists in binding and neutralizing some members of the transforming growth factor-β superfamily such as activin and bone morphogenic proteins. Emerging evidence indicates that this molecule may also play a role in the malignant progression of several human tumors including prostate cancer. In particular, recent findings suggest that, in this tumor, follistatin may also contribute to the formation of bone metastasis through multiple mechanisms, some of which are not related to its specific activin or bone morphogenic proteins’ inhibitory activity. This review provides insight into the most recent advances in understanding the role of follistatin in the prostate cancer progression and discusses the clinical and therapeutic implications related to these findings.
Sepporta, M.V., Tumminello, F.M., Flandina, C., Crescimanno, M., Giammanco, M., La Guardia, M., et al. (2013). Follistatin as potential therapeutic target in prostate cancer. TARGETED ONCOLOGY, 8(00) [DOI 10.1007/s11523-013-0268-7].
File in questo prodotto:
File Dimensione Formato  
10.1007_s11523-013-0268-7.pdf

accesso aperto

Descrizione: review
Dimensione 597.15 kB
Formato Adobe PDF
597.15 kB Adobe PDF Visualizza/Apri
FLS rev Targ Oncol 2013.pdf

accesso aperto

Dimensione 597.15 kB
Formato Adobe PDF
597.15 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10447/70447
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 22
  • ???jsp.display-item.citation.isi??? 20
social impact